HomeTagsRepotrectinib

repotrectinib

Healthcare

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or...

News Desk - May 31, 2023

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for repotrectinib, a next-generation tyrosine...

spot_img

Hot Topics

Read Magazine’s Weekly News Roundup With BAE Systems, Messer, Irdeto, OneStream, Pfizer, And More!

Capgemini Named Leader in IDC Worldwide Sustainability

Element Energy Boosts Second-Life Battery Deployment